ACTEMRA® (tocilizumab) was the first RA treatment to directly block the action of a protein in your body called interleukin-6 (IL-6). This protein is believed to play a part in RA.

​

ACTEMRA is used:

• To treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease modifying antirheumatic drug (DMARD) has been used and did not work well

• To treat adults with giant cell arteritis (GCA)

• To treat patients with active polyarticular juvenile idiopathic arthritis (PJIA) 2 years of age and older 

• To treat patients with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older

• For slowing the rate of decline in lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD) (also known as scleroderma-associated ILD).

• To treat hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation.

• ACTEMRA is not approved for subcutaneous use in people with COVID-19.

​​

It is not known if ACTEMRA is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.